Evaluate Ltd., a London, UK-based provider of commercial intelligence and predictive analytics to the pharmaceutical industry, completed an acquisition of Black Swan Analysis, a London, UK-based consultancy specializing in asset valuations and epidemiology.
The amount of the deal was not disclosed.
The acquisition directly aligns with Evaluate’s core strategy of providing complete and dynamic valuations of pharmaceutical assets, radically transforming client confidence in their strategic portfolio decisions.
Founded in 2007 and led by Nic Talbot-Watt, Chief Executive Officer, Black Swan Analysis is a consultancy that provides analyses, valuations, commercialisation plans, and strategic insight to companies in the healthcare industry, with a focus on bespoke epidemiology and segmentation. Additional core competencies include asset valuation, modelling and market forecasting, and portfolio and lifecycle optimization. They have a global client base which includes Top 25 pharmaceutical companies as well as biotech and tech transfer offices.
Led by Deborah Kobewka, Chief Executive Officer, Evaluate provides commercial intelligence for the pharmaceutical industry and their advisors. Its platform offers dynamic insights into asset risk and value alongside a comprehensive view of the pharmaceutical portfolio landscape Vantage – its independent editorial team – provides news and insights into current and future industry developments.